Ind-Swift Laboratories Ltd.
Snapshot View

82.15 -5.45 ▼-6.2%

05 August 2021, 04:00:00 P.M.
Volume: 83,857

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.indswiftlabs.com
Financial Indicators
Market Cap 485.40 Cr.
Earnings per share (EPS) -0.53 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 32.75 Trailing Twelve Months Ending 2021-03
Book Value / Share 66.35 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.24 Calculated using Price: 82.15
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 5.91 Cr. 59,086,860 Shares
FaceValue 10
Company Profile

Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry. 

Ind-Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its strength in organic synthetic chemistry resulted in the company emerging as the pioneer for a number of products both in the national and international markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it began establishing a presence in the highly regulated markets of the world.

Over a short period of time, Ind-Swift Laboratories Ltd. has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries. Not only are the company's plants built as per USFDA, the company employs current Good Manufacturing Practices (cGMP) also, which are recognised and accepted in the stringent regulated markets. This includes a responsible commitment to the environment.   To leverage its quality commitment, the Company has drawn out a long term strategy of emerging as a powerful force in the regulated markets as drugs worth over US$ 80 billion goes off patent during this decade.

The company's shares are listed on the Bombay, National, Ludhiana and Delhi stock exchanges.

Product range of the company include:

  • Macrolide antibiotics
  • Cardiovascular
  • Anti histamine
  • Anti diabetic
  • Analgesic
  • Aromatase inhibtors
  • Anti depressant
  • Alcohol absistence

MANUFACTURING

Ind-Swift's manufacturing facilities are second to none, and in fact has grown over the years to accommodate a wide range of products. However, even with the spiraling increase in production, it has never compromised on Quality, which has always remained its mantra.

The company has put to operation three new manufacturing facilities covered under its Rs 1 billion expansion plans. The three facilities were a dedicated facility to manufacture Statins ( installed capacity of 40TPA) , a new dedicated facility for an Anti-Histamine drug ( installed capacity 27 TPA) and a New API facility at Samba, Jammu (installed capacity of 50TPA ) . All these facilities conform to USFDA standards and have been put to commercial production. The new facility at Jammu is situated in a tax free zone and shall be entitled to tax holiday for a period of ten years.

Strict Quality Control

Equipped with state-of-the-art quality testing equipment and well trained personnel, Ind-Swift maintains strict quality control, storage to delivery in accordance with GMP and ISO 9002. Quality of products meet the respective requirement of USP/BP/EP/JP etc., as per the international quality standards.

Manufacturing Facilities

  • 1,50,000 sq. ft. covered area
  • 5 Dedicated Blocks operating as per US FDA guidelines.
  • 132 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 245 kilo liters)
  • 3 Automated Fluidized Bed Coaters with capacity of manufacturing 3 MT of Granules per month.
  • cGMP Pilot Plant having 7 reaction vessels with capacities ranging from 250 to 1000 liters. (Total Volume 3.63 kilo liters)
  • Fully Automated Solvent Recovery System
  • Biological Waste Water Treatment Plant

Future plans

While development of new molecules will remain its core activity in the post patent era the Company will also focus on alternate and non-infringing routes for the drugs whose patent will expire in coming years.

To enter the regulated markets like USA, EU, Australia, and New Zealand, the company is focusing on getting its manufacturing plant approved by regulatory agencies like USFDA, TGA and MCA.

A new R&D Center with investment of $ 5 Million is already planned in Mohali with a focus to develop NCEs.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-6.22%
1 Week
-26.45%
1 Month
-15.05%
3 Month
+3.14%
6 Month
+17.95%
1 Year
+129.15%
2 Year
+156.32%
5 Year
+116.47%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 16.50 -21.56 -27.88 -36.36 -23.11 -15.89 7.89 8.99 -5.56
Return on Capital Employed (%) 11.74 1.24 -1.46 -1.52 1.40 2.19 4.59 9.25 6.04
Return on Assets (%) 4.51 -5.13 -5.18 -5.22 -2.65 -1.86 1.11 1.53 -1.17

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 825 853 725 595 517 531 553 588 641
Non Curr. Liab. 777 859 983 811 717 495 438 901 828
Curr. Liab. 618 663 630 833 951 1,005 936 356 323
Minority Int.
Equity & Liab. 2,219 2,376 2,339 2,239 2,185 2,031 1,927 1,845 1,792
Non Curr. Assets 1,223 1,351 1,350 1,319 1,264 1,202 1,088 1,009 929
Curr. Assets 997 1,025 989 920 922 829 839 836 863
Misc. Exp. not W/O
Total Assets 2,219 2,376 2,339 2,239 2,185 2,031 1,927 1,845 1,792

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 1,409 1,136 965 660 653 697 763 757 780
Other Income 34 18 14 22 16 23 26 37 33
Total Income 1,443 1,154 979 683 669 720 788 794 813
Total Expenditure -1,231 -1,065 -906 -572 -546 -591 -628 -630 -636
PBIDT 212 89 73 111 123 129 160 163 177
Interest -85 -140 -117 -117 -106 -90 -35 -92 -107
Depreciation -40 -54 -66 -84 -85 -88 -87 -104 -90
Taxation 3 1 20 24 24 16 -14 -21 -1
Exceptional Items 0 -14 -33 -53 -15 -5 -2 83
PAT 89 -118 -122 -119 -59 -39 22 29 -21

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 73 -47 66 98 79 96 73 -64 125
Cash Fr. Inv. -204 -48 -27 -36 -30 -31 -17 -12 -9
Cash Fr. Finan. 125 66 -38 -64 -48 -69 -62 100 -133
Net Change -6 -29 0 -1 2 -4 -6 23 -17
Cash & Cash Eqvt 47 18 21 20 22 16 9 30 11

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 52.16 52.16 52.16 42.00 42.00 42.00 42.00 42.00 42.00
Public 47.84 47.84 47.84 58.00 58.00 58.00 58.00 58.00 58.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 86.87 86.87 86.87 86.87 86.87 86.87 86.87 86.87 86.87

Announcements View Details

Sat, 31 Jul 2021
Board Meeting Intimation for Notice Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015.
IND-SWIFT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 inter alia to consider and approve Standalone and Consolidated Un-audited Financial Results for the First Quarter ended 30th June 2021.
Fri, 30 Jul 2021
Outcome Of Board Meeting
Outcome of Board Meeting
Fri, 16 Jul 2021
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015
Reporting under Violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations 2015

Technical Scans View Details

Wed, 04 Aug 2021
S Close Below Last Week Low
S Close Below Last Month Low
CCI Oversold Zone CCI Oversold Zone
Tue, 03 Aug 2021
Higher Delivery Quantity Higher Delivery Quantity
Close Crossing Last Month Low Close Crossing Last Month Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%